| Dr Muhammad Shoaib Afridi, MD | |
|
1840 Amherst St, Winchester, VA 22601-2808 | |
| (540) 536-2270 | |
| (540) 536-7847 |
| Full Name | Dr Muhammad Shoaib Afridi |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Location | 1840 Amherst St, Winchester, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902169741 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0101258715 (Virginia) | Secondary |
| 208M00000X | Hospitalist | 0101258715 (Virginia) | Primary |
| Entity Name | Cooperative Healthcare Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417979402 PECOS PAC ID: 9830093640 Enrollment ID: O20031124000222 |
News Archive
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the mortality rate is around 25 per cent from each case.
› Verified 1 days ago
| Entity Name | Health Services Of Central Georgia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184679482 PECOS PAC ID: 9638076730 Enrollment ID: O20031217000270 |
News Archive
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the mortality rate is around 25 per cent from each case.
› Verified 1 days ago
| Entity Name | Ctca Physicians Group Of Georgia, Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447520333 PECOS PAC ID: 4880841212 Enrollment ID: O20120820001117 |
News Archive
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the mortality rate is around 25 per cent from each case.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Muhammad Shoaib Afridi, MD 136 Linden Dr, Suite 104, Winchester, VA 22601-6900 Ph: (540) 678-3588 | Dr Muhammad Shoaib Afridi, MD 1840 Amherst St, Winchester, VA 22601-2808 Ph: (540) 536-2270 |
News Archive
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.
Staphylococcus aureus is a major human pathogen prone to developing antibiotic resistance, causing 120,000 cases of bloodstream infections every year in the United States and over 5000 in Australia; the mortality rate is around 25 per cent from each case.
› Verified 1 days ago
Akua Essiam, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-4334 | |
Ramez Issam Emile Alyacoub, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8000 | |
Corissa Nicole Hockman, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-8000 Fax: 540-836-3286 | |
Gaurav T Parikh, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-2270 Fax: 540-536-7847 | |
Jeyandra Selvam, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1840 Amherst St, Winchester, VA 22601 Phone: 540-536-2270 Fax: 540-536-7847 |